FDA: ADHD Meds Not Linked to Higher Risk of Serious Heart Events

Washington Drug Letter
The FDA will not change its recommendations for use of attention deficit hyperactivity disorder (ADHD) drugs, the agency said Dec. 12, offering data from two studies that found the drugs did not increase the risk of serious adverse cardiovascular events in adults.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00